RAPT - Company ID 0001673772
The table below shows RAPT Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$83.30M | -$97.05M | -$70.77M | -$61.03M | -$40.49M | -$35.47M |
| Capital expenditure | $122.00K | $1.13M | $845.00K | $755.00K | $398.00K | $888.00K |
| Investing cash flow | $52.70M | $104.13M | -$45.49M | -$81.35M | -$87.44M | -$843.00K |
| Dividends paid | - | - | - | - |
RAPT Therapeutics, Inc. reported operating cash flow of -$83.30M for fiscal year 2024. That is up 14.2% from -$97.05M in fiscal 2023. Over the 7 fiscal years shown, operating cash flow declined from -$32.95M (FY 2018) to -$83.30M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $152.85M | $1.45M | $131.18M | $141.48M | $75.46M | $49.90M |